Myriad Investor Day 2023 replay is now available. Watch now
Trust Myriad to deliver what no one else can:
Since we launched the first full-length gene sequencing test for hereditary breast cancer in 1996, more than 2 million people have trusted their hereditary cancer genetic testing to Myriad. This is because we are committed to providing the highest-quality laboratory testing and delivering accurate results that you and your healthcare professional can use to make better, more informed decisions in just 14 days or less.
Learn more about our commitment to quality:
Download Myriad’s Quality Assurance White Paper.
*Based on internal validation data.
Quick — name three diseases that affect humans. We bet you came up with some of the most well-known, such as heart disease, cancer, Alzheimer’s, and COVID-19. Those are all extremely common, affe...